Invivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of “Hold” from Brokerages

Shares of Invivyd, Inc. (NASDAQ:IVVD) have received an average rating of “Hold” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $8.00.

A number of equities research analysts have issued reports on IVVD shares. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday. BTIG Research reissued a “buy” rating and set a $10.00 target price on shares of Invivyd in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a report on Wednesday, April 29th. Finally, HC Wainwright reissued a “buy” rating on shares of Invivyd in a report on Thursday, May 14th.

Invivyd Price Performance

Shares of IVVD stock opened at $1.04 on Wednesday. The company’s fifty day simple moving average is $1.49 and its two-hundred day simple moving average is $1.89. Invivyd has a 1 year low of $0.48 and a 1 year high of $3.07. The stock has a market capitalization of $306.39 million, a price-to-earnings ratio of -3.35 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. The business had revenue of $13.74 million for the quarter, compared to the consensus estimate of $18.04 million. Equities research analysts anticipate that Invivyd will post -0.43 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Courier Capital LLC bought a new position in shares of Invivyd in the fourth quarter worth $25,000. Chicago Partners Investment Group LLC bought a new position in shares of Invivyd in the first quarter worth $25,000. Bronte Capital Management Pty Ltd. bought a new position in shares of Invivyd in the fourth quarter worth $27,000. DRW Securities LLC bought a new position in shares of Invivyd in the fourth quarter worth $27,000. Finally, ProShare Advisors LLC bought a new position in shares of Invivyd in the fourth quarter worth $30,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.